Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Covid has helped the company with consumers more aware of health. They beat sale estimates last quarter but missed on EPS. It’s trading within its expected growth rate. The health trend should be sustained even after covid. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Covid has helped the company with consumers more aware of health. They beat sale estimates last quarter but missed on EPS. It’s trading within its expected growth rate. The health trend should be sustained even after covid. Unlock Premium - Try 5i Free
He likes the trend towards health and wellness through supplements and protein shakes. The company has been given a license to sell their branded product in China. His fund will continue to hold this stock.
(A Top Pick July 20/17, Up 56%) He looks for companies that dominate their market. This is the number one consumer healthcare brand. More than the next 5 largest competitors combined. It was a show-me story at the time. It needs to penetrate other geographical markets like China for continued growth. It is fairly valued at this price.
(A Top Pick July 20/17, Up 56%) He looks for companies that dominate their market. This is the number one consumer healthcare brand. More than the next 5 largest competitors combined. It was a show-me story at the time. It needs to penetrate other geographical markets like China for continued growth. It is fairly valued at this price.
Smaller cap than she would buy. Vitamin manufacturer and retailer. A good one to own.
It is the most prominent name in wellness and vitamins. This company is becoming globally entrenched, but it is very Canadian. It will carry on growing. It has had great numbers. They are at the low end of the price range as holistic people would be willing to pay three times more for the pills. He thinks it has growth potential. (Analysts’ target: $22.25).
It is the most prominent name in wellness and vitamins. This company is becoming globally entrenched, but it is very Canadian. It will carry on growing. It has had great numbers. They are at the low end of the price range as holistic people would be willing to pay three times more for the pills. He thinks it has growth potential. (Analysts’ target: $22.25).
It is the MacDonald’s of the vitamin business. It is the number one Canadian consumer health brand. They have more market share than their 5 biggest peers combined. They have exposure in China. He thinks it will be a success-IPO story like DOL-T. It is now going to be a show-me story as they grow their top line.
It is the MacDonald’s of the vitamin business. It is the number one Canadian consumer health brand. They have more market share than their 5 biggest peers combined. They have exposure in China. He thinks it will be a success-IPO story like DOL-T. It is now going to be a show-me story as they grow their top line.
Jamieson Wellness is a Canadian stock, trading under the symbol JWEL-T on the Toronto Stock Exchange (JWEL-CT). It is usually referred to as TSX:JWEL or JWEL-T
In the last year, 5 stock analysts published opinions about JWEL-T. 5 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Jamieson Wellness.
Jamieson Wellness was recommended as a Top Pick by Christine Poole on 2020-12-14. Read the latest stock experts ratings for Jamieson Wellness.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered Jamieson Wellness In the last year. It is a trending stock that is worth watching.
On 2021-01-15, Jamieson Wellness (JWEL-T) stock closed at a price of $37.14.